ATOS (Atossa Therapeutics) Treasury Stock: $-1.48 Mil (As of Mar. 2026)


ATOS Atossa Therapeutics Inc ATOS
26 GF Score
Price $1.97
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics Treasury Stock?

Atossa Therapeutics ATOS +6.45% 26 Treasury Stock is $-1.48 Mil as of Mar. 2026. GuruFocus rates ATOS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Atossa Therapeutics's treasury stock for the quarter that ended in Mar. 2026 was $-1.48 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Atossa Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Atossa Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics Treasury Stock Chart

Atossa Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -1.48 -1.48 -1.48

Atossa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.48 -1.48 -1.48 -1.48 -1.48
ATOS
26GF Score
Atossa Therapeutics Inc ATOS
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atossa Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $-1.48 Mil mean?
Atossa Therapeutics (ATOS) has a Treasury Stock of $-1.48 Mil as of Mar. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Atossa Therapeutics and its competitors.
Is Atossa Therapeutics' Treasury Stock too high?
Atossa Therapeutics' current Treasury Stock is $-1.48 Mil. Overall, Atossa Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' Treasury Stock compare to QNCX and ZIVO?
Atossa Therapeutics' Treasury Stock of $-1.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Atossa Therapeutics and its competitors. Atossa Therapeutics's current Treasury Stock is $-1.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (ATOS) has a current Treasury Stock of $-1.48 Mil. The current Treasury Stock is $-1.48 Mil. Atossa Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Atossa Therapeutics (ATOS), the current Treasury Stock is $-1.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atossa Therapeutics Business Description

Other Exchanges ATOS:MexicoYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score

Get the complete analysis for ATOS

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.97
Price